Patria Investments (NYSE:PAX) vs. BR Biopharma (NASDAQ:BRBI) Financial Contrast

BR Biopharma (NASDAQ:BRBI) and Patria Investments (NYSE:PAX) are both small-cap finance companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Earnings and Valuation

This table compares BR Biopharma and Patria Investments”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BR Biopharma	$2.23 billion	0.04	$31.36 million	$0.08	91.25
Patria Investments	$428.00 million	1.46	$73.40 million	$0.44	21.36

Patria Investments has lower revenue, but higher earnings than BR Biopharma. Patria Investments is trading at a lower price-to-earnings ratio than BR Biopharma, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for BR Biopharma and Patria Investments, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BR Biopharma	1	1	0	0	1.50
Patria Investments	3	1	1	0	1.60

Patria Investments has a consensus target price of $12.75, suggesting a potential upside of 35.64%. Given Patria Investments’ stronger consensus rating and higher possible upside, analysts clearly believe Patria Investments is more favorable than BR Biopharma.

Profitability

This table compares BR Biopharma and Patria Investments’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BR Biopharma	N/A	N/A	N/A
Patria Investments	19.91%	38.68%	15.84%

Insider & Institutional Ownership

96.3% of Patria Investments shares are owned by institutional investors. 58.1% of Patria Investments shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility & Risk

BR Biopharma has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500. Comparatively, Patria Investments has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.

Dividends

BR Biopharma pays an annual dividend of $0.42 per share and has a dividend yield of 5.8%. Patria Investments pays an annual dividend of $0.65 per share and has a dividend yield of 6.9%. BR Biopharma pays out 525.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Patria Investments pays out 147.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Patria Investments is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Patria Investments beats BR Biopharma on 14 of the 16 factors compared between the two stocks.

About BR Biopharma

BRBI BR Partners S.A., through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners S.A. is based in S?o Paulo, Brazil.

About Patria Investments

Patria Investments Limited operates as a private market investment firm focused on investing in Latin America. The company offers asset management services to investors focusing on private equity funds, infrastructure development funds, co-investments funds, constructivist equity funds, and real estate and credit funds. Patria Investments Limited was founded in 1994 and is headquartered in Grand Cayman, the Cayman Islands.